TY - JOUR
AU - RECOVERY Collaborative Group
PY - 2022
DA - February
TI - Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial
JO - The Lancet
EP - 676
VL - 399
IS - 10325
DO - https://doi.org/10.1016/S0140-6736(22)00163-5
AB - Casirivimab and imdevimab are non-competing monoclonal antibodies that bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike glycoprotein, blocking viral entry into host cells. We aimed to evaluate the efficacy and safety of casirivimab and imdevimab administered in combination in patients admitted to hospital with COVID-19.
PB - Elsevier
UR - https://hdl.handle.net/2164/18986
KW - Coronavirus (COVID-19)
KW - Hospital care
ER